Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cabazitaxel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Cabazitaxel. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-000823-38 Sponsor Protocol Number: CABADARO Start Date*: 2020-05-08
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Study on the pharmacokinetic interaction between cabazitaxel and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002993-11 Sponsor Protocol Number: 2016-02 Start Date*: 2016-10-26
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: A single arm phase 2 multicenter study determining the response to Cabazitaxel in metastatic prostate cancer (mCRPC) patients with AR-V7 positive circulating tumor cells (CTCs)
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005504-34 Sponsor Protocol Number: C-II-010 Start Date*: 2014-07-11
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research - EWIV
    Full Title: Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)
    Medical condition: Stage II with advanced Castration-Resistant Prostate Cancer (CRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003792-41 Sponsor Protocol Number: DAROTAXEL Start Date*: 2023-05-26
    Sponsor Name:Erasmus MC
    Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001938-42 Sponsor Protocol Number: UCL-ONCO2011-01 Start Date*: 2012-01-24
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy
    Medical condition: To evaluate the efficacy of cabazitaxel in patients with palliative head and neck previously treated with platinum-based therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003156-39 Sponsor Protocol Number: FUOGT2011-1 Start Date*: 2011-08-29
    Sponsor Name:Tampere University Hospital
    Full Title: OPEN, SINGLE-ARM, MULTICENTER, PHASE II TRIAL INVESTIGATING THE SAFETY OF BIWEEKLY CABAZITAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH A DOCETAXEL-CONTA...
    Medical condition: This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) previously treated with docetaxel containing regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001253-41 Sponsor Protocol Number: GOIM16002-CABONESTUDY Start Date*: 2018-03-12
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel
    Medical condition: 1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002184-42 Sponsor Protocol Number: TED12689 Start Date*: 2016-02-19
    Sponsor Name:Sanofi-aventis
    Full Title: A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Tumors of the Central Nervous System
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061268 Malignant nervous system neoplasm PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001062-41 Sponsor Protocol Number: 13-005 Start Date*: 2013-06-12
    Sponsor Name:RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A) [...]
    1. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    2. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    3. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    Full Title: Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy
    Medical condition: high-risk prostata cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004485-21 Sponsor Protocol Number: HE9A/14 Start Date*: 2015-04-03
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
    Medical condition: Castration resistant bone metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022163-35 Sponsor Protocol Number: EFC11785 Start Date*: 2011-04-04
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostat...
    Medical condition: metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) HU (Completed) BE (Completed) ES (Completed) GB (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021128-92 Sponsor Protocol Number: CABAZ_C_05331 Start Date*: 2010-11-11
    Sponsor Name:sanofi-aventis groupe
    Full Title: MULTICENTRE, SINGLE-ARM, OPEN LABEL CLINICAL TRIAL INTENDED TO PROVIDE EARLY ACCESS TO CABAZITAXEL IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAX...
    Medical condition: Metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DK (Completed) ES (Completed) IT (Completed) SE (Completed) FI (Completed) AT (Completed) PT (Completed) HU (Completed) IE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005116-28 Sponsor Protocol Number: 38495 Start Date*: 2012-09-10
    Sponsor Name:
    Full Title: A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial
    Medical condition: Metastatic prostate cancer/bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003346-40 Sponsor Protocol Number: CABARESC Start Date*: 2011-12-06
    Sponsor Name:Erasmus MC-Daniël den Hoed
    Full Title: A phase II study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel (Jevtana®): A randomised, open-label multicenter study: CABARESC
    Medical condition: metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005194-32 Sponsor Protocol Number: CRANIAL Start Date*: 2013-06-28
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer
    Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059282 Metastases to central nervous system PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000996-17 Sponsor Protocol Number: 201200099617 Start Date*: 2012-06-18
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life.
    Medical condition: Subjects affected by metastatic castration refractory prostate cancer progressed or intolerant to a previous docetaxel-based chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002826-55 Sponsor Protocol Number: SECAVIN-12 Start Date*: 2012-10-17
    Sponsor Name:Associació Per a la Recerca Oncològica (APRO)
    Full Title: A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium
    Medical condition: metastatic or locally advanced transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001506-96 Sponsor Protocol Number: TCD12128 Start Date*: 2012-03-27
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC) whose Disease has Progressed after Docetaxe...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003625-97 Sponsor Protocol Number: HE11B11 Start Date*: 2012-07-24
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes
    Medical condition: HER-2 negative metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004937-29 Sponsor Protocol Number: NL55621.029.15 Start Date*: 2016-06-14
    Sponsor Name:VU University Medical Center
    Full Title: Towards early identification of response to CABAZItaxel in patients with metastatic castration-resistant prostate cancer: potential of 18F-Choline PET-CT (CABAZIPET).
    Medical condition: Metastatic castration-resistant prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:40:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA